Naarden, The Netherlands, 16 April 2021 – BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma has announced the appointment of Laura Asbjornsen as its Head of Communications.
As lead for communications at both BGV and its platform partner Forbion, Laura is charged with conceptualisation and implementation of all aspect of communications both internally and externally. Media relations, stakeholder engagement, marketing communications and digital media will also form part of her remit at the Amsterdam-based company.
Laura most recently worked for a Dutch private equity group as its Senior Communications Manager. She spent over two years developing and executing the company’s communications strategy. Prior to this, Laura held communications roles at various organisations across the world, including communications agencies, corporate entities, governments and NGOs.
BGV’s Managing Partner Edward van Wezel, commented, “It has become imperative at this juncture to streamline our communications activities to commensurate the growth we have experienced. BGV occupies a special place in the life sciences venture capital industry concentrating on the European startup space, and as we expand our portfolio, a strategic communications approach is required to support that growth.“
For more information please contact:
For further information:
Edward van Wezel
Tel: +31 35 69 930 00
Tel: +31 35 69 930 00
Notes to Editors
About BioGeneration Ventures (BGV)
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €250 million ($300 million) of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.
BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.